<DOC>
	<DOCNO>NCT01812538</DOCNO>
	<brief_summary>This study conduct evaluate effectiveness DIC075V ventricular repolarization healthy subject compare placebo single dose DIC075V administer intravenously ( IV ) evaluate ECG assay sensitivity evaluate baseline-adjusted effect single oral ( PO ) moxifloxacin 400 mg dose ventricular repolarization healthy subject compare placebo . Other secondary objective follow : - To evaluate effect DIC075V ventricular repolarization healthy subject compare placebo Tmax diclofenac hydroxypropyl-β-cyclodextrin ( HPβCD ) . - To determine pharmacokinetic/pharmacodynamic ( PK/PD ) relationship duration QTc interval diclofenac HPβCD plasma concentration . - Obtain additional pharmacokinetic ( PK ) information diclofenac HPβCD healthy subject . - Provide additional safety information .</brief_summary>
	<brief_title>A Randomized , Single-Dose , Comparative , Positive Placebo Controlled , Four-Way , Four Period , Cross-Over Study Evaluate Effect DIC075V QTc Intervals Healthy Subjects</brief_title>
	<detailed_description>This randomize , single-dose , comparative , positive placebo control , 4 period , 4-way crossover study evaluate effect DIC075V QTc interval healthy subject . Two dos DIC075V test include moxifloxicin positive control normal saline placebo arm . On 4 separate occasion separate least 72 hour , subject give single IV oral ( moxifloxicin ) treatment . ECGs acquire continuous Holter monitor select timepoints evaluate . These ECGs 15 second duration extract triplicate . Monitoring continue 24 hour treatment . The primary ECG endpoint baseline-adjusted QTc use Fridericia correction ( QTcF ) . Secondary endpoint include baseline-adjusted QTc use Bazett correction formula ( QTcB ) . In addition , population-specific regression model construct QT plot RR ( time elapse 2 consecutive R-waves ) . Finally , QT parameter explore graphically relation PK variable Cmax , Tmax AUC .</detailed_description>
	<criteria>1 . Willing able provide sign informed consent , include Health Insurance Portability Accountability Act ( HIPAA ) Authorization . 2 . Healthy adult male and/or female subject , 1850 year age . 3 . Body mass index ( BMI ) 1830 , inclusive . 4 . Medically healthy clinically significant screen result ( laboratory profile , medical history , ECGs , physical exam ) . 5 . Normal blood pressure ( &lt; 140 mmHg systolic &lt; 90 mmHg diastolic ) . 6 . Normal 12lead ECG ( QTc interval &lt; 450 millisecond ( m ) males &lt; 470 m female ) : 1 . Consistent sinus rhythm 2 . No clinically significant conduction disorder 3 . PR interval 120 230 m 4 . HR ≤100 bpm ≥40 bpm 5 . QRS interval ≤110 m 6 . QT interval consistently analyze . 7 . No medical history cardiac disease family history QT prolongation . 8 . No clinically significant electrolyte abnormality . 9 . Subjects calculate creatinine clearance great &gt; 80 ml/min . 10 . Female subject childbearing potential negative serum pregnancy test Screening Checkin either sexually inactive ( abstinent ) 14 day prior Screening throughout study use two follow acceptable birth control method : Intrauterine device ( IUD ) place least 2 month prior Study Day 2 ; Barrier method ( condom diaphragm ) spermicide least 14 day prior screen study completion ; Hormonal contraceptive least 3 month prior Study Day 2 completion study ; Surgical sterilization ( vasectomy ) partner least 6 month prior Study Day 2 . 11 . Female subject nonchildbearing potential negative serum pregnancy test Screening Checkin meet least one follow criterion : Naturally postmenopausal minimum 2 consecutive year prior Study Day 2 ; Surgically sterile ( bilateral tubal ligation surgery least 6 month prior Study Day 2 , hysterectomy , bilateral oophorectomy surgery least 2 month prior Study Day 2 ) . 1 . History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease . 2 . History invasive cancer within past 5 year ( exclude nonmelanoma skin cancer ) . 3 . History hypersensitivity allergy quinolone class antibiotic ; diclofenac NSAIDs ; HPβCD excipients DIC075V ( monothioglycerol , sodium hydroxide , hydrochloric acid , water injection ) . 4 . History presence alcoholism drug abuse within past 2 year . 5 . Use tobacco product within previous 6 month . 6 . Donation blood within 45 day prior Study Day 2 . 7 . Plasma donation within 30 day prior Study Day 2 . 8 . Participation study investigational drug within 90 day prior Study Day 2 . 9 . Participation another clinical trial within 45 day prior Study Day 2 . 10 . Female subject pregnant lactating . 11 . Hemoglobin reference range test laboratory . 12 . Clinically significant abnormal laboratory value . 13 . Abnormal ECG . The abnormality ECG could QRS duration &gt; 110 m , first degree heart block define PR duration &gt; 230 m , second third degree heart block , complete heart block . 14 . Male subject screen QTc interval ≥450 m female subject QTc interval ≥470 ms. 15 . Presence untreated uncontrolled blood pressure , i.e. , systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg . 16 . Angina , uncontrolled hypertension , clinically significant bradycardia , clinically significant cardiac arrhythmia , clinically significant cardiovascular abnormality . 17 . History clinically significant syncope . 18 . History clinically significant arrhythmia ( e.g. , ventricular arrhythmia , supraventricular arrhythmia , atrial fibrillation ) . 19 . History clinically significant psychiatric illness would prevent subject provide valid Informed Consent . 20 . Positive laboratory test result hepatitis B , hepatitis C , HIV , control Substances , cotinine , alcohol . 21 . With exception hormonal contraceptive hormone replacement therapy female least 3 month piror Study Day 2 , prescription overthecounter ( OTC ) medication , include topical medication , vitamin , herbal dietary supplements/remedies ( e.g. , Saint John 's Wort Milk Thistle ) , within 14 day Study Day 2 . 22 . With exception hormonal contraceptive hormone replacement therapy female least 3 month prior Study Day 2 , plan concomitant medication duration study ( except acetaminophen 2 g/day ) . 23 . History additional risk factor Torsade de Pointes ( e.g. , heart failure , hypokalemia , history drown survival , family history Long QT Syndrome , family history Short QT Syndrome , family history unexplainable early sudden death ) . 24 . History asthma attack , hive , allergic reaction aspirin NSAID medicine . 25 . History coronary bypass operation . 26 . History bleed gastric duodenal ulcer . 27 . History skin reaction take medication . 28 . History hepatic disorder symptom associate hepatic disorder , e.g. , nausea , tiredness , itching , flulike symptom , vomit blood , blood subject 's bowel movement , and/or melana . 29 . History clinically significant seizure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>